Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 7/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | KLK1 | P06870 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29227917 | 0.85 | CNR1 (0.42) | NOTUMKCNMA1F11KLKB1SCN9A | |
| SCHEMBL30271680 | 0.84 | NOTUM (0.45) | NOTUMKCNMA1F11KLKB1JAK2 | |
| SCHEMBL16971673 | 0.84 | NOTUM (0.45) | NOTUMKCNMA1F11KLKB1JAK2 | |
| SCHEMBL30271742 | 0.74 | NOTUM (0.42) | NOTUMKCNMA1F11KLKB1JAK2 | |
| SCHEMBL16754018 | 0.74 | NOTUM (0.53) | NOTUMKCNMA1HDAC8SCN9A | |
| SCHEMBL30995043 | 0.74 | NOTUM (0.53) | NOTUMKCNMA1HDAC8SCN9A | |
| SCHEMBL16971428 | 0.74 | NOTUM (0.42) | NOTUMKCNMA1F11KLKB1JAK2 | |
| SCHEMBL30995034 | 0.74 | F11 (0.48) | F11KLK1 | |
| SCHEMBL29227914 | 0.74 | F11 (0.48) | F11KLK1 | |
| SCHEMBL20348658 | 0.72 | NOTUM (0.42) | NOTUMKCNMA1F11KLKB1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F11 | NOTUM 3281/4885KCNMA1 612/4885F11 3/4885 |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | NOTUM 3281/4885KCNMA1 612/4885F11 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.